BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $1.47 billion. The enterprise value is $1.99 billion.
| Market Cap | 1.47B |
| Enterprise Value | 1.99B |
Important Dates
The next confirmed earnings date is Monday, August 5, 2024, before market open.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 206.38 million shares outstanding. The number of shares has increased by 9.31% in one year.
| Shares Outstanding | 206.38M |
| Shares Change (YoY) | +9.31% |
| Shares Change (QoQ) | +2.26% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 89.81% |
| Float | 191.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.15 |
| Forward PS | 3.48 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.73
| Current Ratio | 3.73 |
| Quick Ratio | 3.33 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.98 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -40.90% |
| Return on Capital (ROIC) | -23.83% |
| Revenue Per Employee | $663,050 |
| Profits Per Employee | -$389,151 |
| Employee Count | 536 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 0.18 |
Taxes
In the past 12 months, BCRX has paid $4,000 in taxes.
| Income Tax | 4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.99% in the last 52 weeks. The beta is 1.88, so BCRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | -2.99% |
| 50-Day Moving Average | 6.39 |
| 200-Day Moving Average | 5.73 |
| Relative Strength Index (RSI) | 59.81 |
| Average Volume (20 Days) | 3,535,730 |
Short Selling Information
The latest short interest is 17.88 million, so 8.66% of the outstanding shares have been sold short.
| Short Interest | 17.88M |
| Short Previous Month | 29.67M |
| Short % of Shares Out | 8.66% |
| Short % of Float | 9.35% |
| Short Ratio (days to cover) | 4.83 |
Income Statement
In the last 12 months, BCRX had revenue of $355.40 million and -$208.59 million in losses. Loss per share was -$1.07.
| Revenue | 355.40M |
| Gross Profit | 350.28M |
| Operating Income | -89.78M |
| Pretax Income | -208.58M |
| Net Income | -208.59M |
| EBITDA | -101.68M |
| EBIT | -103.23M |
| Loss Per Share | -$1.07 |
Balance Sheet
The company has $338.35 million in cash and $852.90 million in debt, giving a net cash position of -$514.55 million or -$2.49 per share.
| Cash & Cash Equivalents | 338.35M |
| Total Debt | 852.90M |
| Net Cash | -514.55M |
| Net Cash Per Share | -$2.49 |
| Equity (Book Value) | -476.17M |
| Book Value Per Share | -2.31 |
| Working Capital | 327.18M |
Cash Flow
In the last 12 months, operating cash flow was -$101.31 million and capital expenditures -$2.24 million, giving a free cash flow of -$103.56 million.
| Operating Cash Flow | -101.31M |
| Capital Expenditures | -2.24M |
| Free Cash Flow | -103.56M |
| FCF Per Share | -$0.50 |
Margins
Gross margin is 98.56%, with operating and profit margins of -25.26% and -58.69%.
| Gross Margin | 98.56% |
| Operating Margin | -25.26% |
| Pretax Margin | -58.69% |
| Profit Margin | -58.69% |
| EBITDA Margin | -28.61% |
| EBIT Margin | -29.05% |
| FCF Margin | -29.14% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.31% |
| Shareholder Yield | -9.31% |
| Earnings Yield | -14.16% |
| FCF Yield | -7.03% |
Analyst Forecast
The average price target for BCRX is $14.67, which is 105.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.67 |
| Price Target Difference | 105.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 18.72% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -3.33 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.33 |
| Piotroski F-Score | 3 |